Bio Technology General - BTGC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Technology General - BTGC

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bosco who wrote (1880)	7/14/1999 3:01:00 PM
From: Dave O.	Read Replies (1) of 2028

< The curious thing is that the stock has been in a recovery mode in the past couple of months. So what gives? > I think the "problem" revolves around Oxandrin. Scripts continue to increase, which is good news. But Olsten, their distributor, apparently has so much inventory they need to work off that it is expected that shipments to Olsten will be less than in 1998. Remember Oxandrin represented over 55% of BTGC revenues in 1998, over $40 million of the $76 million. And it was expetced that Oxandrin would be near $49 million in 1999, per Merrill Lynch analysts report. It'll take some significant outperformance in their other drugs to make up for the expected shortfall in Oxandrin sales. This was all pretty obvious if one looked at the recent 10-Q's. Accounts Receivable were staggering and it seems as if they stuffed the channel (shipping Oxandrin to Olsten) last year. And they record revenues when they ship product, which is now adversely impacting things. I'm in for the longer term so I'm not too concerned, the 0.10 EPS was much better than I expected. Dave

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next